Small Molecules

24 Mar 2018 Janssen Announces Positive CHMP Opinion for JULUCATM (dolutegravir/rilpivirine)
24 Mar 2018 CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets
24 Mar 2018 Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
24 Mar 2018 Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
23 Mar 2018 Lokelma approved in the EU for the treatment of adults with hyperkalaemia
23 Mar 2018 Anticancer Agent LENVIMA® (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
23 Mar 2018 Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma
23 Mar 2018 vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
23 Mar 2018 Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial
22 Mar 2018 ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
22 Mar 2018 Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
22 Mar 2018 Processa Pharmaceuticals Announces That It Has Been Assigned The License For The Clinical Stage Compound CTP-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions
21 Mar 2018 First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy
21 Mar 2018 Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
21 Mar 2018 Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
21 Mar 2018 Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease
20 Mar 2018 Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
20 Mar 2018 U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
19 Mar 2018 Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB
19 Mar 2018 Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials of HTX-011 in Bunionectomy and Hernia Repair
19 Mar 2018 Forendo Pharma receives €3 million loan from Business Finland to develop novel treatments for endometriosis
19 Mar 2018 eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
16 Mar 2018 Q Biomed Inc. announces FDA filing for approval of a new manufacturing facility for non-opioid Strontium Chloride SR89 Injection USP for relief of cancer bone pain
16 Mar 2018 Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome
16 Mar 2018 AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing